Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial (vol 9, 22, 2016)

    Thumbnail
    Download
    Citations
    Web of Science
    Altmetric
    4
    Author
    Foss, F; Horwitz, S; Pro, B; Prince, HM; Sokol, L; Balser, B; Wolfson, J; Coiffier, B
    Date
    2017-09-18
    Source Title
    Journal of Hematology and Oncology
    Publisher
    BIOMED CENTRAL LTD
    University of Melbourne Author/s
    Prince, Henry
    Affiliation
    Medicine and Radiology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Foss, F., Horwitz, S., Pro, B., Prince, H. M., Sokol, L., Balser, B., Wolfson, J. & Coiffier, B. (2017). Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial (vol 9, 22, 2016). JOURNAL OF HEMATOLOGY & ONCOLOGY, 10 (1), https://doi.org/10.1186/s13045-017-0518-8.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/256955
    DOI
    10.1186/s13045-017-0518-8

    Export Reference in RIS Format     

    Publisher licence
    CC BY
    Collections